FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385360705> ?p ?o ?g. }

• W4385360705 endingPage "32" @default.
• W4385360705 startingPage "24" @default.
• W4385360705 abstract "This symposium took place during the 60th European Renal Association (ERA) Congress, held in Milan, Italy, and virtually. Bengt Fellström, Uppsala University, Sweden, described the relationship between IgA nephropathy (IgAN) and gastrointestinal mucosal reactivity. Fellström then outlined the history of Nefecon (Calliditas Therapeutics, Stockholm, Sweden, and STADA Arzneimittel, Bad Vilbel, Germany), which was developed based on the assumption that the gut plays a major role in the pathophysiology of the disease, and that there was a high unmet need for a well-tolerated and effective therapy. Nefecon was specifically designed to target the origins of IgAN. A Phase IIb clinical trial showed, for the first time, that 9 months of treatment with Nefecon was well-tolerated and effective in patients at risk of disease progression. Jonathan Barratt, University of Leicester, UK, and John Walls Renal Unit, Leicester General Hospital, UK, presented biomarker data supporting the efficacy data in clinical trials, and presented topline data from Part B of the Phase III NefIgArd trial. Specifically, the results demonstrated an average 5.05 mL/min/1.73 m2 estimated glomerular filtration rate (eGFR) treatment benefit in favour of Nefecon versus placebo over 2 years. This confirmed that the eGFR benefit of 9 months of active treatment with Nefecon was maintained during the observational follow-up. The eGFR benefit with Nefecon versus placebo was consistent regardless of baseline urine protein-creatinine ratio (UPCR). At 2 years, the 30% reduction in UPCR in the Nefecon versus placebo arm was similar to the percentage reduction at the end of the 9-month treatment period, plus 15 months follow-up off treatment. Patients treated with Nefecon experienced decreasing levels of proteinuria while on active treatment and for 3 months afterwards, suggesting a continued biologic effect. Barratt presented UK registry data showing that, despite being treated with the current standard of care for IgAN, three-quarters of adults and half of paediatric patients developed kidney failure or died within 20 years of disease onset. Barratt suggested a paradigm shift in the treatment approach for all patients with IgAN, who have a risk of developing kidney failure in their lifetime." @default.
• W4385360705 created "2023-07-29" @default.
• W4385360705 creator A5089856774 @default.
• W4385360705 date "2023-07-27" @default.
• W4385360705 modified "2023-09-23" @default.
• W4385360705 title "Filling the Gap by Targeting the Gut: First Disease-Modifying Treatment Approved for IgA Nephropathy" @default.
• W4385360705 cites W1975208318 @default.
• W4385360705 cites W2052324927 @default.
• W4385360705 cites W2079362912 @default.
• W4385360705 cites W2096977413 @default.
• W4385360705 cites W2108850130 @default.
• W4385360705 cites W2141675485 @default.
• W4385360705 cites W2159666276 @default.
• W4385360705 cites W2313007433 @default.
• W4385360705 cites W3033261685 @default.
• W4385360705 cites W3080629152 @default.
• W4385360705 cites W3200553460 @default.
• W4385360705 cites W3215284682 @default.
• W4385360705 cites W4254192089 @default.
• W4385360705 cites W4306757577 @default.
• W4385360705 cites W4365457345 @default.
• W4385360705 cites W4367175044 @default.
• W4385360705 doi "https://doi.org/10.33590/emjnephrol/10302464" @default.
• W4385360705 hasPublicationYear "2023" @default.
• W4385360705 type Work @default.
• W4385360705 citedByCount "0" @default.
• W4385360705 crossrefType "journal-article" @default.
• W4385360705 hasAuthorship W4385360705A5089856774 @default.
• W4385360705 hasBestOaLocation W43853607051 @default.
• W4385360705 hasConcept C126322002 @default.
• W4385360705 hasConcept C126894567 @default.
• W4385360705 hasConcept C134018914 @default.
• W4385360705 hasConcept C142724271 @default.
• W4385360705 hasConcept C159641895 @default.
• W4385360705 hasConcept C185592680 @default.
• W4385360705 hasConcept C204787440 @default.
• W4385360705 hasConcept C23131810 @default.
• W4385360705 hasConcept C27081682 @default.
• W4385360705 hasConcept C2779134260 @default.
• W4385360705 hasConcept C2780306776 @default.
• W4385360705 hasConcept C2781184683 @default.
• W4385360705 hasConcept C2781197716 @default.
• W4385360705 hasConcept C535046627 @default.
• W4385360705 hasConcept C55493867 @default.
• W4385360705 hasConcept C555293320 @default.
• W4385360705 hasConcept C71924100 @default.
• W4385360705 hasConcept C90924648 @default.
• W4385360705 hasConceptScore W4385360705C126322002 @default.
• W4385360705 hasConceptScore W4385360705C126894567 @default.
• W4385360705 hasConceptScore W4385360705C134018914 @default.
• W4385360705 hasConceptScore W4385360705C142724271 @default.
• W4385360705 hasConceptScore W4385360705C159641895 @default.
• W4385360705 hasConceptScore W4385360705C185592680 @default.
• W4385360705 hasConceptScore W4385360705C204787440 @default.
• W4385360705 hasConceptScore W4385360705C23131810 @default.
• W4385360705 hasConceptScore W4385360705C27081682 @default.
• W4385360705 hasConceptScore W4385360705C2779134260 @default.
• W4385360705 hasConceptScore W4385360705C2780306776 @default.
• W4385360705 hasConceptScore W4385360705C2781184683 @default.
• W4385360705 hasConceptScore W4385360705C2781197716 @default.
• W4385360705 hasConceptScore W4385360705C535046627 @default.
• W4385360705 hasConceptScore W4385360705C55493867 @default.
• W4385360705 hasConceptScore W4385360705C555293320 @default.
• W4385360705 hasConceptScore W4385360705C71924100 @default.
• W4385360705 hasConceptScore W4385360705C90924648 @default.
• W4385360705 hasLocation W43853607051 @default.
• W4385360705 hasOpenAccess W4385360705 @default.
• W4385360705 hasPrimaryLocation W43853607051 @default.
• W4385360705 hasRelatedWork W1544023406 @default.
• W4385360705 hasRelatedWork W1973741567 @default.
• W4385360705 hasRelatedWork W1974378936 @default.
• W4385360705 hasRelatedWork W2008644969 @default.
• W4385360705 hasRelatedWork W2046899919 @default.
• W4385360705 hasRelatedWork W2130073437 @default.
• W4385360705 hasRelatedWork W3117263584 @default.
• W4385360705 hasRelatedWork W3204052984 @default.
• W4385360705 hasRelatedWork W393698729 @default.
• W4385360705 hasRelatedWork W4296385806 @default.
• W4385360705 isParatext "false" @default.
• W4385360705 isRetracted "false" @default.
• W4385360705 workType "article" @default.